{"id":3732,"date":"2018-12-05T14:13:08","date_gmt":"2018-12-05T13:13:08","guid":{"rendered":"http:\/\/www.epitype.de\/?p=3732&lang=en"},"modified":"2018-12-05T14:13:08","modified_gmt":"2018-12-05T13:13:08","slug":"oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018","status":"publish","type":"post","link":"https:\/\/www.epitype.de\/en\/blog\/2018\/12\/05\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\/","title":{"rendered":"Oncgnostics GmbH Presents New Clinical Data on GynTect\u00ae Precision Diagnostics at EUROGIN 2018"},"content":{"rendered":"

Oncgnostics will discuss new clinical data with gynaecological key opinion leaders at EUROGIN 2018<\/a><\/i><\/h1>\n
\n

SAN FRANCISCO, CA, USA, November 29, 2018 — Oncgnostics GmbH presents new clinical data on GynTect\u00ae<\/a> Precision Diagnostics for triage of unclear cervical cancer screening tests.<\/p>\n

Oncgnostics GmbH, a Jena\/Germany based company, has developed GynTect\u00ae for precision detection of cervical cancer. GynTect\u00ae was tested and validated in clinical trials on more than 3,000 samples with a remarkable detection score of 100% in all cervical cancer cases. Moreover, GynTect\u00ae identifies all relevant pre-cancerous lesions due to its first-of-a-kind prognostic value.<\/p>\n

\u201cWe have concluded further clinical trials on the performance of GynTect\u00ae in comparison to alternative cervical cancer triage approaches. These results are very convincing and we are happy to present them in 5 talks at the EUROGIN 2018 conference in Lisbon next week\u201d, states Dr. Alfred Hansel, Oncgnostics Chief Executive Officer.<\/p>\n

Together with CSO Dr. Martina Schmitz and three Oncgnostics R&D specialists for cervical cancer and head-and-neck cancer diagnostics, Oncgnostics will discuss the new clinical data with gynecological key opinion leaders at Oncgnostics booth for precision cancer diagnostics.<\/p>\n

Oncgnostics technology has been exclusively licensed out in 2017 to Sinopharm Group for the greater China region.<\/p>\n

Biotech Alliances International Inc., a Silicon Valley-based healthcare-focused investment bank, is serving as the lead investment banker to Oncgnostics globalization and partnering strategy. Meetings with Oncgnostics Management Team can be coordinated at EUROGIN 2018 or JPM2019.<\/p>\n

 <\/p>\n

About Oncgnostics GmbH<\/p>\n

Oncgnostics GmbH, founded in early 2012 as a spin-off from the Jena University women\u2019s hospital, is a molecular diagnostics company specializing in cancer diagnostics. Oncgnostics tests target epigenetic changes, so-called DNA methylations, that typically occur in cancer cells. The patented biomarkers, which are evaluated using a specific algorithm, are the core of the products and provide the basis for the company\u2019s activities.<\/p>\n

About Biotech Alliances International Inc.<\/p>\n

Biotech Alliances International Inc.<\/a> is a San Francisco-based investment bank serving life sciences companies, private equity, and venture capital funds. It provides independent financial and strategic advice including corporate finance, mergers & acquisitions, partnering & licensing, and strategic consulting.<\/p>\n

Dr. Franck Brinkhaus
\nBiotech Alliances International Inc
\n+1 650-868-8511<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Oncgnostics will discuss new clinical data with gynaecological key opinion leaders at EUROGIN 2018 SAN FRANCISCO, CA, USA, November 29, 2018 — Oncgnostics GmbH presents new clinical data on GynTect\u00ae […]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[57,59],"tags":[366,78,178,92,79,474,373,121,464,152],"class_list":["post-3732","post","type-post","status-publish","format-standard","hentry","category-blog","category-press-releases","tag-biotech-alliances-international-inc","tag-cervical-cancer","tag-cervical-carcinoma","tag-cervixcarzinom","tag-diagnostics","tag-eurogin-en","tag-eurogin-2018","tag-gynecology","tag-gyntect-en","tag-prevention"],"yoast_head":"\nOncgnostics GmbH Presents New Clinical Data on GynTect\u00ae Precision Diagnostics at EUROGIN 2018 - Epitype GmbH<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.epitype.de\/en\/blog\/2018\/12\/05\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncgnostics GmbH Presents New Clinical Data on GynTect\u00ae Precision Diagnostics at EUROGIN 2018 - Epitype GmbH\" \/>\n<meta property=\"og:description\" content=\"Oncgnostics will discuss new clinical data with gynaecological key opinion leaders at EUROGIN 2018 SAN FRANCISCO, CA, USA, November 29, 2018 — Oncgnostics GmbH presents new clinical data on GynTect\u00ae […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.epitype.de\/en\/blog\/2018\/12\/05\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"Epitype GmbH\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/oncgnostics\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-05T13:13:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.epitype.de\/wp-content\/uploads\/2015\/03\/oncgnostics-logo2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"340\" \/>\n\t<meta property=\"og:image:height\" content=\"156\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"TowerPR\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"TowerPR\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/blog\\\/2018\\\/12\\\/05\\\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/blog\\\/2018\\\/12\\\/05\\\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\\\/\"},\"author\":{\"name\":\"TowerPR\",\"@id\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/#\\\/schema\\\/person\\\/4b9b03a47d4ad1a3629af15e8fdc908b\"},\"headline\":\"Oncgnostics GmbH Presents New Clinical Data on GynTect\u00ae Precision Diagnostics at EUROGIN 2018\",\"datePublished\":\"2018-12-05T13:13:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/blog\\\/2018\\\/12\\\/05\\\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\\\/\"},\"wordCount\":360,\"keywords\":[\"Biotech Alliances International Inc.\",\"cervical cancer\",\"cervical carcinoma\",\"Cervixcarzinom\",\"diagnostics\",\"Eurogin\",\"Eurogin 2018\",\"gynecology\",\"GynTect\",\"prevention\"],\"articleSection\":[\"Blog\",\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/blog\\\/2018\\\/12\\\/05\\\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\\\/\",\"url\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/blog\\\/2018\\\/12\\\/05\\\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\\\/\",\"name\":\"Oncgnostics GmbH Presents New Clinical Data on GynTect\u00ae Precision Diagnostics at EUROGIN 2018 - Epitype GmbH\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/#website\"},\"datePublished\":\"2018-12-05T13:13:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/#\\\/schema\\\/person\\\/4b9b03a47d4ad1a3629af15e8fdc908b\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/blog\\\/2018\\\/12\\\/05\\\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.epitype.de\\\/en\\\/blog\\\/2018\\\/12\\\/05\\\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/blog\\\/2018\\\/12\\\/05\\\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncgnostics GmbH Presents New Clinical Data on GynTect\u00ae Precision Diagnostics at EUROGIN 2018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/\",\"name\":\"epitype GmbH\",\"description\":\"Molecular cancer diagnostics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/#\\\/schema\\\/person\\\/4b9b03a47d4ad1a3629af15e8fdc908b\",\"name\":\"TowerPR\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/847b96fd8f4d2ac81f5abb1f54f41e177c97c1c10c8309e3e382e16b325cab02?s=96&d=blank&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/847b96fd8f4d2ac81f5abb1f54f41e177c97c1c10c8309e3e382e16b325cab02?s=96&d=blank&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/847b96fd8f4d2ac81f5abb1f54f41e177c97c1c10c8309e3e382e16b325cab02?s=96&d=blank&r=g\",\"caption\":\"TowerPR\"},\"url\":\"https:\\\/\\\/www.epitype.de\\\/en\\\/blog\\\/author\\\/towerpr\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncgnostics GmbH Presents New Clinical Data on GynTect\u00ae Precision Diagnostics at EUROGIN 2018 - Epitype GmbH","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.epitype.de\/en\/blog\/2018\/12\/05\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\/","og_locale":"en_US","og_type":"article","og_title":"Oncgnostics GmbH Presents New Clinical Data on GynTect\u00ae Precision Diagnostics at EUROGIN 2018 - Epitype GmbH","og_description":"Oncgnostics will discuss new clinical data with gynaecological key opinion leaders at EUROGIN 2018 SAN FRANCISCO, CA, USA, November 29, 2018 — Oncgnostics GmbH presents new clinical data on GynTect\u00ae […]","og_url":"https:\/\/www.epitype.de\/en\/blog\/2018\/12\/05\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\/","og_site_name":"Epitype GmbH","article_publisher":"https:\/\/www.facebook.com\/oncgnostics\/","article_published_time":"2018-12-05T13:13:08+00:00","og_image":[{"width":340,"height":156,"url":"https:\/\/www.epitype.de\/wp-content\/uploads\/2015\/03\/oncgnostics-logo2.png","type":"image\/png"}],"author":"TowerPR","twitter_card":"summary_large_image","twitter_misc":{"Written by":"TowerPR","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.epitype.de\/en\/blog\/2018\/12\/05\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\/#article","isPartOf":{"@id":"https:\/\/www.epitype.de\/en\/blog\/2018\/12\/05\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\/"},"author":{"name":"TowerPR","@id":"https:\/\/www.epitype.de\/en\/#\/schema\/person\/4b9b03a47d4ad1a3629af15e8fdc908b"},"headline":"Oncgnostics GmbH Presents New Clinical Data on GynTect\u00ae Precision Diagnostics at EUROGIN 2018","datePublished":"2018-12-05T13:13:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.epitype.de\/en\/blog\/2018\/12\/05\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\/"},"wordCount":360,"keywords":["Biotech Alliances International Inc.","cervical cancer","cervical carcinoma","Cervixcarzinom","diagnostics","Eurogin","Eurogin 2018","gynecology","GynTect","prevention"],"articleSection":["Blog","Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.epitype.de\/en\/blog\/2018\/12\/05\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\/","url":"https:\/\/www.epitype.de\/en\/blog\/2018\/12\/05\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\/","name":"Oncgnostics GmbH Presents New Clinical Data on GynTect\u00ae Precision Diagnostics at EUROGIN 2018 - Epitype GmbH","isPartOf":{"@id":"https:\/\/www.epitype.de\/en\/#website"},"datePublished":"2018-12-05T13:13:08+00:00","author":{"@id":"https:\/\/www.epitype.de\/en\/#\/schema\/person\/4b9b03a47d4ad1a3629af15e8fdc908b"},"breadcrumb":{"@id":"https:\/\/www.epitype.de\/en\/blog\/2018\/12\/05\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.epitype.de\/en\/blog\/2018\/12\/05\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.epitype.de\/en\/blog\/2018\/12\/05\/oncgnostics-presents-new-clinical-data-on-gyntect-at-eurogin-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.epitype.de\/en\/"},{"@type":"ListItem","position":2,"name":"Oncgnostics GmbH Presents New Clinical Data on GynTect\u00ae Precision Diagnostics at EUROGIN 2018"}]},{"@type":"WebSite","@id":"https:\/\/www.epitype.de\/en\/#website","url":"https:\/\/www.epitype.de\/en\/","name":"epitype GmbH","description":"Molecular cancer diagnostics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.epitype.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.epitype.de\/en\/#\/schema\/person\/4b9b03a47d4ad1a3629af15e8fdc908b","name":"TowerPR","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/847b96fd8f4d2ac81f5abb1f54f41e177c97c1c10c8309e3e382e16b325cab02?s=96&d=blank&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/847b96fd8f4d2ac81f5abb1f54f41e177c97c1c10c8309e3e382e16b325cab02?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/847b96fd8f4d2ac81f5abb1f54f41e177c97c1c10c8309e3e382e16b325cab02?s=96&d=blank&r=g","caption":"TowerPR"},"url":"https:\/\/www.epitype.de\/en\/blog\/author\/towerpr\/"}]}},"_links":{"self":[{"href":"https:\/\/www.epitype.de\/en\/wp-json\/wp\/v2\/posts\/3732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.epitype.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.epitype.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.epitype.de\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.epitype.de\/en\/wp-json\/wp\/v2\/comments?post=3732"}],"version-history":[{"count":0,"href":"https:\/\/www.epitype.de\/en\/wp-json\/wp\/v2\/posts\/3732\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.epitype.de\/en\/wp-json\/wp\/v2\/media?parent=3732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.epitype.de\/en\/wp-json\/wp\/v2\/categories?post=3732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.epitype.de\/en\/wp-json\/wp\/v2\/tags?post=3732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}